Casdin Capital focuses on investing in disruptive life science companies, particularly those in biotechnology, genomics, and healthcare tools and diagnostics. Their strategy involves a long-term, multi-stage approach to support transformative innovation across the sector.
82% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 2 prior). Average disclosed round size is $101.1M (across 48 rounds with reported amounts).
Portfolio
49
Fund Size
$1.6B
Top Stage
Series B
Last 12 Mo
1
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
49 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Apella | Series B | $80M | Jan 2026 |
 TMRW Life Sciences | Series D | $28M | Jul 2024 |
 BridgeBio Oncology Therapeutics (BBOT) | Growth | $200M | May 2024 |
 Remix Therapeutics | Series C | $60M | Jan 2024 |
 Thyme Care | Series B | $60M | Aug 2023 |
 Flare Therapeutics Inc. | Series B | $123M | Mar 2023 |
 Chroma Medicine | Series B | $135M | Mar 2023 |
 Vector BioMed | Seed | — | Jan 2023 |
 Auron Therapeutics | Series A | $48M | Jul 2022 |
 Invetx | Series B | $60.5M | May 2022 |
 Arzeda | Series B | $33M | Mar 2022 |
 Volta Labs | Series A | $20M | Mar 2022 |
 Molecular Assemblies Inc. | Series B | $25.8M | Mar 2022 |
 Creyon Bio | Seed | $40M | Mar 2022 |
 Leyden Laboratories B.V. | Series B | $140M | Jan 2022 |
| OONI | Series B | $75M | Jan 2022 |
 Verana Health | Series E | $150M | Jan 2022 |
 Meiogenix | Series A | $13M | Dec 2021 |
 Beacon Biosignals | Series A | $27M | Nov 2021 |
 TrialSpark | Series C | $156M | Sep 2021 |
 Genomatica | Series C | $118M | Jul 2021 |
| TMRW Life Sciences | Series C | $105M | Jul 2021 |
 Umoja Biopharma | Series B | $210M | Jun 2021 |
 Mnemo Therapeutics | Series A | $90M | Jun 2021 |
 Vedere Bio II, Inc. | Series A | $77M | May 2021 |
Page 1 of 2
Top Co-Investors
GV (Google Ventures)10 shared
Alexandria Venture Investments7 shared
DCVC5 shared
Perceptive Advisors5 shared
Samsara BioCapital5 shared
Section 325 shared
ARCH Venture Partners5 shared
Nextech Invest4 shared
Andreessen Horowitz4 shared
Atlas Venture4 shared
RA Capital Management4 shared
Redmile Group4 shared
Dragoneer Investment Group3 shared
Invus3 shared
Sofinnova Partners3 shared
The Column Group3 shared
Avidity Partners3 shared
F-Prime Capital3 shared
NEA (New Enterprise Associates)3 shared
Viking Global Investors3 shared
Last updated: 15 April 2026